These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35233908)

  • 1. The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
    Cherney DZI; Cosentino F; Pratley RE; Dagogo-Jack S; Frederich R; Maldonado M; Liu J; Pong A; Liu CC; Cannon CP;
    Diabetes Obes Metab; 2022 Jun; 24(6):1114-1122. PubMed ID: 35233908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
    Dagogo-Jack S; Pratley RE; Cherney DZI; McGuire DK; Cosentino F; Shih WJ; Liu J; Frederich R; Mancuso JP; Raji A; Gantz I
    BMJ Open Diabetes Res Care; 2021 Oct; 9(1):. PubMed ID: 34620621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial.
    Cherney DZI; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley RE; Frederich R; Maldonado M; Liu CC; Pong A; Cannon CP;
    Am J Nephrol; 2022; 53(7):516-525. PubMed ID: 35691283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.
    Sridhar VS; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley RE; Cater NB; Noyes Essex M; Mancuso JP; Zhao Y; Cherney DZI
    Diabetes Obes Metab; 2024 Nov; 26(11):5336-5346. PubMed ID: 39219437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.
    Cherney DZI; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Frederich R; Maldonado M; Liu CC; Liu J; Pong A; Cannon CP;
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1345-1354. PubMed ID: 34497110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
    Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP;
    Diabetologia; 2021 Jun; 64(6):1256-1267. PubMed ID: 33665685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
    Lingvay I; Greenberg M; Gallo S; Shi H; Liu J; Gantz I
    Diabetes Obes Metab; 2021 Jul; 23(7):1640-1651. PubMed ID: 33769675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
    Segar MW; Kolkailah AA; Frederich R; Pong A; Cannon CP; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley RE; Liu CC; Maldonado M; Liu J; Cater NB; Pandey A; Cherney DZI
    Diabetes Obes Metab; 2022 Sep; 24(9):1829-1839. PubMed ID: 35603908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.
    Pratley RE; Cannon CP; Cherney DZI; Cosentino F; McGuire DK; Essex MN; Lawrence D; Jones PLS; Liu J; Adamsons I; Dagogo-Jack S
    Lancet Healthy Longev; 2023 Apr; 4(4):e143-e154. PubMed ID: 37003273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
    Dagogo-Jack S; Liu J; Eldor R; Amorin G; Johnson J; Hille D; Liao Y; Huyck S; Golm G; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 Mar; 20(3):530-540. PubMed ID: 28921862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
    Cherney DZI; Heerspink HJL; Frederich R; Maldonado M; Liu J; Pong A; Xu ZJ; Patel S; Hickman A; Mancuso JP; Gantz I; Terra SG
    Diabetologia; 2020 Jun; 63(6):1128-1140. PubMed ID: 32236732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
    Cannon CP; McGuire DK; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Charbonnel B; Shih WJ; Gallo S; Masiukiewicz U; Golm G; Cosentino F; Lauring B; Terra SG;
    Am Heart J; 2018 Dec; 206():11-23. PubMed ID: 30290289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
    Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Liu J; Pong A; Gantz I; Frederich R; Mancuso JP; Pratley RE
    Diabetes Obes Metab; 2022 Jul; 24(7):1245-1254. PubMed ID: 35266296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
    Wojeck BS; Inzucchi SE; Neeland IJ; Mancuso JP; Frederich R; Masiukiewicz U; Cater NB; McGuire DK; Cannon CP; Yaggi HK
    Sleep Breath; 2023 May; 27(2):669-672. PubMed ID: 35596030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
    Rosenstock J; Frias J; Páll D; Charbonnel B; Pascu R; Saur D; Darekar A; Huyck S; Shi H; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Mar; 20(3):520-529. PubMed ID: 28857451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
    Aronson R; Frias J; Goldman A; Darekar A; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Jun; 20(6):1453-1460. PubMed ID: 29419917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
    Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
    Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial.
    Cherney DZI; Cosentino F; McGuire DK; Kolkailah AA; Dagogo-Jack S; Pratley RE; Frederich R; Maldonado M; Liu CC; Cannon CP;
    Kidney Int Rep; 2023 Apr; 8(4):746-753. PubMed ID: 37069970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.